Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

被引：0

作者：

Karimi, Yasmin H. ^{[1
]}

Thieblemont, Catherine ^{[2
]}

Ghesquieres, Herve ^{[3
]}

Cheah, Chan Y. ^{[4
,5
]}

Clausen, Michael Roost ^{[6
]}

Cunningham, David ^{[7
]}

Jurczak, Wojciech ^{[8
]}

Linton, Kim M. ^{[9
,10
]}

Hutchings, Martin ^{[11
,12
]}

Phillips, Tycel ^{[13
]}

Farooq, Umar ^{[14
]}

Kim, Won Seog ^{[15
]}

Dinh, Minh H. ^{[16
]}

Ghosh, Jagannath ^{[17
]}

Pallai, Rajash ^{[17
]}

Wielgos-Bonvallet, Monica ^{[17
]}

Eskelund, Christian ^{[18
]}

Lugtenburg, Pieternella J. ^{[19
]}

Vose, Julie M. ^{[20
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA

[2] Univ Paris, APHP, Hop St Louis, Hematooncol, Paris, France

[3] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France

[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[5] Univ Western Australia, Nedlands, WA, Australia

[6] Vejle Hosp, Vejle, Denmark

[7] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[8] MSC Natl Res Inst Oncol, Krakow, Poland

[9] Univ Manchester, Christie NHS Fdn Trust, Manchester Canc Res Ctr, Manchester, Lancs, England

[10] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[11] Rigshosp, Copenhagen, Denmark

[12] Univ Copenhagen, Copenhagen, Denmark

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] Univ Iowa, Iowa City, IA USA

[15] Samsung Med Ctr, Seoul, South Korea

[16] AbbVie, N Chicago, IL USA

[17] Genmab, Plainsboro, NJ USA

[18] Genmab, Copenhagen, Denmark

[19] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[20] Univ Nebraska Med Ctr, Omaha, NE USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

ALL; bispecific; large B-cell lymphoma; hematologic malignancy; non-Hodgkin lymphoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-191

引用

页码：S461 / S462

页数：2

共 50 条

[21] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
L Giaccone
M Festuccia
F Zallio
R Sorasio
L Brunello
E Maffini
C Dellacasa
R Passera
G Iovino
S Aydin
M Boccadoro
U Vitolo
N Mordini
M Pini
A Busca
B Bruno
Bone Marrow Transplantation, 2017, 52 : 1208 - 1211
[22] Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
Ladbury, Colton
Dandapani, Savita
Hao, Claire
Fabros, Mildred
Amini, Arya
Sampath, Sagus
Glaser, Scott
Sokolov, Karen
Yeh, Jekwon
Baird, John H.
Thiruvengadam, Swetha Kambhampati
Herrera, Alex
Mei, Matthew
Nikolaenko, Liana
Shouse, Geoffrey
Budde, Lihua E.
CANCERS, 2023, 15 (06)
[23] Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up
Song, Yuqin
Zhou, Keshu
Li, Dengju
Hu, Jianda
Zou, Dehui
Gao, Sujun
Yang, Haiyan
Zhang, Huilai
Ji, Jie
Xu, Wei
Feng, Ru
Jin, Jie
Lyu, Fangfang
Fang, Cheng
Xu, Sheng
Zhu, Jun
BLOOD, 2023, 142
[24] Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and long-term follow-up in 24 patients
Jonak, C.
Paniec, P.
Porkert, S.
Valencak, J.
MELANOMA RESEARCH, 2016, 26 : E115 - E115
[25] Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
Bharadwaj, Sushma
Lau, Eric
Goyal, Anmol
Hamilton, Mark P.
Srinagesh, Hrishikesh
Jensen, Alexandria
Syal, Shriya
Mallampet, Jayasindhu
Latchford, Theresa
Sahaf, Bita
Weng, Wen-Kai
Smith, Melody
Maecker, Holden T.
Frank, Matthew J.
Miklos, David B.
Dahiya, Saurabh
BLOOD, 2023, 142
[26] Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.
Coombs, Catherine Callaghan
Shah, Nirav Niranjan
Jurczak, Wojciech
Woyach, Jennifer Ann
Cheah, Chan
Patel, Krish
Maddocks, Kami J.
Wang, Yucai
Muehlenbein, Catherine E.
Wang, Chunxiao
Abhyankar, Sarang
Tsai, Donald Edward
Eyre, Toby A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] The First Retrospective Commercial Claims-Based Analysis of CAR T Treated Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Purdum, Anna
Johnson, Jonathan
Bonagura, Anthony
Nyamutswa, Liliosa
Elliott, Caitlin
Lal, Lincy S.
BLOOD, 2020, 136
[28] Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
Zinzani, Pier Luigi
Pellegrini, Cinzia
Derenzini, Enrico
Argnani, Lisa
Pileri, Stefano
HEMATOLOGICAL ONCOLOGY, 2013, 31 (04) : 223 - 224
[29] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Topp, Max S.
van Meerten, Tom
Wermke, Martin
Lugtenburg, Elly J.
Minnema, Monique C.
Song, Kevin W.
Thieblemont, Catherine
Jiang, Yizhou
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[30] Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axicel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/ R LBCL): A Multicenter Analysis
Vuyyala, Sowjanya
Corraes, Andre De Menezes Silva
Bailey, Megumi
Iqbal, Madiha
Munoz, Javier L.
Hunter, Bradley
Bansal, Radhika
Patel, Krish
Kharfan-Dabaja, Mohamed A.
Rosenthal, Allison C.
Wang, Yucai
Paludo, Jonas
Johnston, Patrick B.
Bennani, N. Nora
Villasboas, J. C. C.
Durani, Urshila
Ansell, Stephen M.
Lin, Yi
Khurana, Arushi
BLOOD, 2023, 142

← 1 2 3 4 5 →